204 related articles for article (PubMed ID: 27291893)
1. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin R; Lahrmann B; Warsow G; Hübschmann D; Spath C; Walter B; Chen X; Hofer L; Macher-Goeppinger S; Tolstov Y; Korzeniewski N; Duensing A; Grüllich C; Jäger D; Perner S; Schönberg G; Nyarangi-Dix J; Isaac S; Hatiboglu G; Teber D; Hadaschik B; Pahernik S; Roth W; Eils R; Schlesner M; Sültmann H; Hohenfellner M; Grabe N; Duensing S
Nat Commun; 2016 Jun; 7():ncomms11845. PubMed ID: 27291893
[TBL] [Abstract][Full Text] [Related]
2. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
Gerlinger M; Quezada SA; Peggs KS; Furness AJ; Fisher R; Marafioti T; Shende VH; McGranahan N; Rowan AJ; Hazell S; Hamm D; Robins HS; Pickering L; Gore M; Nicol DL; Larkin J; Swanton C
J Pathol; 2013 Dec; 231(4):424-32. PubMed ID: 24122851
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27Kip1: Implications for Spatial Niche Formation and Functional Intratumoral Heterogeneity.
Hou W; Kaczorowski A; Lantwin P; Kippenberger M; Schütz V; Franke D; Dieffenbacher SC; Hohenfellner M; Duensing S
Pathobiology; 2020; 87(2):114-124. PubMed ID: 32229735
[TBL] [Abstract][Full Text] [Related]
4. Parallel evolution of tumour subclones mimics diversity between tumours.
Martinez P; Birkbak NJ; Gerlinger M; McGranahan N; Burrell RA; Rowan AJ; Joshi T; Fisher R; Larkin J; Szallasi Z; Swanton C
J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
[TBL] [Abstract][Full Text] [Related]
5. Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients.
Saout JR; Lecuyer G; Léonard S; Evrard B; Kammerer-Jacquet SF; Noël L; Khene ZE; Mathieu R; Brunot A; Rolland AD; Bensalah K; Rioux-Leclercq N; Lardenois A; Chalmel F
Eur Urol; 2023 May; 83(5):441-451. PubMed ID: 36801089
[TBL] [Abstract][Full Text] [Related]
6. Mutational heterogeneity between different regional tumour grades of clear cell renal cell carcinoma.
Ferronika P; Kats-Ugurlu G; Haryana SM; Utoro T; Rinonce HT; Danarto R; de Lange K; Terpstra MM; Sijmons RH; Westers H; Kok K
Exp Mol Pathol; 2020 Aug; 115():104431. PubMed ID: 32259515
[TBL] [Abstract][Full Text] [Related]
7. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
8. Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.
Miheecheva N; Postovalova E; Lyu Y; Ramachandran A; Bagaev A; Svekolkin V; Galkin I; Zyrin V; Maximov V; Lozinsky Y; Isaev S; Ovcharov P; Shamsutdinova D; Cheng EH; Nomie K; Brown JH; Tsiper M; Ataullakhanov R; Fowler N; Hsieh JJ
Cell Rep; 2022 Aug; 40(7):111180. PubMed ID: 35977503
[TBL] [Abstract][Full Text] [Related]
9. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
10. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer.
Lubbock ALR; Stewart GD; O'Mahony FC; Laird A; Mullen P; O'Donnell M; Powles T; Harrison DJ; Overton IM
BMC Med; 2017 Jun; 15(1):118. PubMed ID: 28648142
[TBL] [Abstract][Full Text] [Related]
11. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Li Y; Lih TM; Dhanasekaran SM; Mannan R; Chen L; Cieslik M; Wu Y; Lu RJ; Clark DJ; Kołodziejczak I; Hong R; Chen S; Zhao Y; Chugh S; Caravan W; Naser Al Deen N; Hosseini N; Newton CJ; Krug K; Xu Y; Cho KC; Hu Y; Zhang Y; Kumar-Sinha C; Ma W; Calinawan A; Wyczalkowski MA; Wendl MC; Wang Y; Guo S; Zhang C; Le A; Dagar A; Hopkins A; Cho H; Leprevost FDV; Jing X; Teo GC; Liu W; Reimers MA; Pachynski R; Lazar AJ; Chinnaiyan AM; Van Tine BA; Zhang B; Rodland KD; Getz G; Mani DR; Wang P; Chen F; Hostetter G; Thiagarajan M; Linehan WM; Fenyö D; Jewell SD; Omenn GS; Mehra R; Wiznerowicz M; Robles AI; Mesri M; Hiltke T; An E; Rodriguez H; Chan DW; Ricketts CJ; Nesvizhskii AI; Zhang H; Ding L;
Cancer Cell; 2023 Jan; 41(1):139-163.e17. PubMed ID: 36563681
[TBL] [Abstract][Full Text] [Related]
13. Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma.
Liu K; Gao R; Wu H; Wang Z; Han G
J Cell Mol Med; 2021 May; 25(9):4260-4274. PubMed ID: 33759378
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC).
Liu S; Li S; Wang Y; Wang F; Zhang L; Xian S; Yang D; Yuan M; Dai F; Zhao X; Liu Y; Jin Y; Zeng Z; Mahgoub OKA; Zhou C; Cheng Y
J Cell Biochem; 2020 Mar; 121(3):2571-2581. PubMed ID: 31823423
[TBL] [Abstract][Full Text] [Related]
15. Features of increased malignancy in eosinophilic clear cell renal cell carcinoma.
Nilsson H; Lindgren D; Axelson H; Brueffer C; Saal LH; Lundgren J; Johansson ME
J Pathol; 2020 Dec; 252(4):384-397. PubMed ID: 32815150
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
17.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
18. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
19. Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness.
Momoi Y; Nishida J; Miyakuni K; Kuroda M; Kubota SI; Miyazono K; Ehata S
Cancer Sci; 2021 Aug; 112(8):3136-3149. PubMed ID: 34091990
[TBL] [Abstract][Full Text] [Related]
20. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
